Document
type: Class

Academic Article
type: Class

Continuant
type: Class

Inglese
type: Language

Entity
type: Class

Generically Dependent Continuant
type: Class

individual
rights: termsOfUse
date: 2026-08-25T15:12:32
publisher: Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study
type: Document
label: RDF description of Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study - http://irises.unibs.it/resource/item/52032

2646029
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study
type: Document
type: Thing
type: Academic Article
most specific type: Academic Article
type: Information Content Entity
related by: 2646029
type: Generically Dependent Continuant
type: Continuant
type: Entity
language: Inglese
type: Article

Article
type: Class

Information Content Entity
type: Class